Our work at Jazz is driven by our enduring commitment to improving the lives of patients and their families. As a long-time leader in sleep medicine, we have come to understand the importance of providing solutions that address patients’ lives holistically, especially for those living with serious, debilitating sleep disorders. We are thrilled by the opportunity to showcase our efforts and research at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS) in Houston. We are excited to build on our leadership by continuing to deliver on our promise of supporting the sleep community.
People living with rare disorders, such as narcolepsy and idiopathic hypersomnia, live with complex and severe conditions, impacting every aspect of a patient’s life from their sleep health to overall well-being.1,2,3 Narcolepsy and idiopathic hypersomnia are both chronic conditions which require lifelong management. Not only can these conditions be life-altering, but they are also often misunderstood and underrecognized.4,5 Additionally, recent research has revealed that both sleep disorders are associated with cardiovascular and cardiometabolic comorbidities.6-10
However, there is still more we can learn about these conditions. It is important for us to continue to expand our understanding of the brain and to further refine and evaluate the options we can bring patients and providers. Grounded in our deep dedication to patients, we persevere in the face of challenges, and dedicate ourselves to delivering innovation that aims to improve the care and daily lives of those we serve.
This is why I am proud of the robust range of data we are presenting at SLEEP 2024 from across our sleep medicine portfolio. These new findings continue to demonstrate our commitment to the sleep community and the importance of addressing the needs of patients living with sleep disorders where there is a high unmet need.
To better serve the sleep community, during SLEEP and beyond, we champion and advocate for patients, caregivers and their families. We also listen to the needs of our patients as their voice is an integral part of our efforts and guides the decisions we make. First, we strive to support people living with hard-to-treat conditions, their caregivers and healthcare providers along their journey by providing resources and information on disease risk factors, signs and symptoms and diagnosis. You can learn more about the resources we have available here. Equally as important, we are also committed to removing barriers to access through our assistance programs.
I want to thank all my colleagues at Jazz, and our community partners, for their continued dedication to pioneering meaningful advancements to improve the lives of those living with these debilitating sleep disorders. I look forward to connecting with the industry's leading experts, partners and researchers at this year’s meeting to better understand patient needs and share insights to collaborate on solutions and redefine possibilities for the sleep community.
1 National Institute of Neurological Disorders and Stroke (NINDS). Narcolepsy. www.ninds.nih.gov. Published 2023. https://www.ninds.nih.gov/health-information/disorders/narcolepsy; Last accessed May 2024.
2Evangelista E, Lopez R, Dauvilliers Y. Update on treatment for idiopathic hypersomnia. Expert Opin Investig Drugs. 2018 Feb;27(2):187-192.
3Ozaki A, Inoue Y, Hayashida K, Nakajima T, Honda M, Usui A, Komada Y, Kobayashi M, Takahashi K. Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naïve patients and the general Japanese population. Sleep Med. 2012 Feb;13(2):200-6.
4Krahn, L.E., Zee, P.C. & Thorpy, M.J. Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know. Adv Ther. 39, 221–243 (2022).
Masri TJ, Gonzales CG, Kushida CA. Idiopathic Hypersomnia. Sleep Med Clin. 2012 June;7(2):283-289.
6Ben-Joseph RH, Saad R, Black J, et al. Cardiovascular burden of narcolepsy disease (CV-BOND): a real-world evidence study. Presented at: 2022 AAN Annual Meeting; April 2-7; Seattle, Washington. Poster 1203.
7Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13-18.
8Ohayon MM, Black J, Lai C, et al. Increased mortality in narcolepsy. Sleep. 2014;37(3):439-444.
9Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488-492.
10Saad R, Lillaney P, Profant D, et al. Cardiovascular Burden of Patients Diagnosed With Idiopathic Hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM). Presented at: Psych Congress 2023; September 6-10; Nashville, Tennessee. Poster 75
